Department of Laboratory Medicine and Pathology, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, Minnesota, USA.
Department of Medicine, Section of Epidemiology and Population Sciences, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas, USA.
Neuro Oncol. 2018 May 18;20(6):810-817. doi: 10.1093/neuonc/nox192.
Single-gene mutation syndromes account for some familial glioma (FG); however, they make up only a small fraction of glioma families. Gliomas can be classified into 3 major molecular subtypes based on isocitrate dehydrogenase (IDH) mutation and 1p/19q codeletion. We hypothesized that the prevalence of molecular subtypes might differ in familial versus sporadic gliomas and that tumors in the same family should have the same molecular subtype.
Participants in the FG study (Gliogene) provided samples for germline DNA analysis. Formalin-fixed, paraffin-embedded tumors were obtained from a subset of FG cases, and DNA was extracted. We analyzed tissue from 75 families, including 10 families containing a second affected family member. Copy number variation data were obtained using a first-generation Affymetrix molecular inversion probe (MIP) array.
Samples from 62 of 75 (83%) FG cases could be classified into the 3 subtypes. The prevalence of the molecular subtypes was: 30 (48%) IDH-wildtype, 21 (34%) IDH-mutant non-codeleted, and 11 (19%) IDH-mutant and 1p/19q codeleted. This distribution of molecular subtypes was not statistically different from that of sporadic gliomas (P = 0.54). Of 10 paired FG samples, molecular subtypes were concordant for 7 (κ = 0.59): 3 IDH-mutant non-codeleted, 2 IDH-wildtype, and 2 IDH-mutant and 1p/19q codeleted gliomas.
Our data suggest that within individual families, patients develop gliomas of the same molecular subtype. However, we did not observe differences in the prevalence of the molecular subtypes in FG compared with sporadic gliomas. These observations provide further insight into the distribution of molecular subtypes in FG.
单基因突变综合征占部分家族性脑胶质瘤(FG);然而,它们只占脑胶质瘤家族的一小部分。脑胶质瘤可基于异柠檬酸脱氢酶(IDH)突变和 1p/19q 联合缺失分为 3 种主要分子亚型。我们假设,在家族性和散发性脑胶质瘤中,分子亚型的流行率可能不同,并且同一家庭的肿瘤应该具有相同的分子亚型。
FG 研究(Gliogene)的参与者提供了种系 DNA 分析的样本。从小部分 FG 病例中获得了福尔马林固定、石蜡包埋的肿瘤,并提取了 DNA。我们分析了来自 75 个家族的组织,其中 10 个家族包含第二个受影响的家族成员。使用第一代 Affymetrix 分子反转探针(MIP)阵列获得了拷贝数变异数据。
75 例 FG 病例中的 62 例(83%)可分为 3 种亚型。分子亚型的患病率为:30 例(48%)IDH 野生型,21 例(34%)IDH 突变非缺失型,11 例(19%)IDH 突变和 1p/19q 联合缺失型。这种分子亚型的分布与散发性脑胶质瘤无统计学差异(P=0.54)。在 10 对 FG 样本中,7 对(κ=0.59)的分子亚型是一致的:3 例 IDH 突变非缺失型,2 例 IDH 野生型,2 例 IDH 突变和 1p/19q 联合缺失型脑胶质瘤。
我们的数据表明,在个体家庭中,患者会发展出相同分子亚型的脑胶质瘤。然而,我们在 FG 与散发性脑胶质瘤中并未观察到分子亚型流行率的差异。这些观察结果进一步深入了解了 FG 中分子亚型的分布。